148) TC genetic test administered by a company compared to a MP because they were less tr |
149) advantage associated with a PDI nomogram compared to a PA nomogram but no differenc |
150) The pathobiology of these 3 strains was compared to a South African NDV strain cla |
151) t-course (n = 122), and outcomes were compared to a control group of early enrol |
152) ledronate-treated rats (n = 18) were then compared to a control group of untreated r |
153) containing monodisperse primary particles compared to a conventional pMDI. |
154) pped by more than 2 m under this scenario compared to a future base condition, and e |
155) lymphoblastic leukemia (SR-ALL) survivors compared to a healthy comparison (HC) grou |
156) individuals with DSM-IV-diagnosed BPD was compared to a nonclinical control sample o |
157) strumental variables (IV) estimate, 34 %) compared to a normal-weight individual. |
158) ure to active beam scanning (ABS) protons compared to a passive delivery system. |
159) children with high-functioning autism as compared to a sample of peers, from the ch |
160) session led by a physical therapist—was compared to a treatment group which receiv |
161) nefit of our proposed marginal model when compared to a two-part mixed model is the |
162) release of Cu B from nanoscale CCS-films compared to that from a conventional CCS f |
163) e contralateral side in the control group compared to that in the BoTA group (P < |
164) 7, and eNOS phosphorylation at Thr495, as compared to that in the control. |
165) es both showed a lower-level distribution compared to that in the plasma, which indi |
166) use calvarial defect model over 4 weeks compared to that in the untreated group. |
167) e pattern accounting for 20% drug release compared to that of OP solution up to 90% |
168) in female Turkish immigrants is higher as compared to that of native-born women of t |
169) bosomal gene was amplified, sequenced and compared to that of other diplozoid taxa. |
170) ein formulations, and its stabilizing was compared to that of other excipients which |
171) ngement of cox2-rrnS in F-type mitogenome compared to that of other freshwater musse |
172) ding 1.0 mg/ml of the UE + HPE extract compared to that of the control (no treatm |
173) to increase the rate of the drug release compared to that of the free drug. |
174) Compared to controls at this stage, exposu |
175) s of animals exposed to d-phenothrin when compared to controls. |
176) of wound contraction and reepithelisation compared to controls. |
177) luteinising hormone (LH) in HCD group as compared to controls. |
178) voxel-wise morphometry in PG subjects as compared to controls. |
179) D was reduced in CHD patients (P<0.05) compared to controls. |
180) novel learning of spatial configurations compared to controls. |
|